This is one of those under-the-radar plays that could really take off soon. I’ve been watching this company for a while now, dropped 50K there in biotech, but retail investors haven’t clued in yet.
The smart money is starting to circle, and I reckon we’re about to see some serious action on the stock. Their flagship product, Mitra, is a game-changer for blood sampling in healthcare and research, which are both booming right now.
Plus, their disruptive tech segment is on track to break even by FY25, and they're forecasting a 30% revenue boost in the second half of FY24—profits are around the corner.Not to mention, the chairman, is heavily invested with a huge stake. When insiders have this much skin in the game, you know they’re backing something big.
On top of that, they’ve got the Hummingbird project a portable environmental testing device that’s already generating buzz and demand. With these innovations coming together, we could see some serious growth—and once retail investors catch wind, expect the stock to start climbing fast if they move into China
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)